MA49881B1 - ANTI CD25 ANTICOPRS OPTIMIZED IN THEIR FC PART INVOLVING THE DEPLETION OF TUMOR-SPECIFIC CELLS - Google Patents

ANTI CD25 ANTICOPRS OPTIMIZED IN THEIR FC PART INVOLVING THE DEPLETION OF TUMOR-SPECIFIC CELLS

Info

Publication number
MA49881B1
MA49881B1 MA49881A MA49881A MA49881B1 MA 49881 B1 MA49881 B1 MA 49881B1 MA 49881 A MA49881 A MA 49881A MA 49881 A MA49881 A MA 49881A MA 49881 B1 MA49881 B1 MA 49881B1
Authority
MA
Morocco
Prior art keywords
depletion
anticoprs
tumor
optimized
specific cells
Prior art date
Application number
MA49881A
Other languages
French (fr)
Other versions
MA49881A (en
Inventor
Anne Goubier
Pascal Merchiers
Josephine Salimu
Corzo Beatriz Goyenechea
Kevin Moulder
Sergio Quezada
Karl Peggs
Vargas Frederick Arce
Isabelle Solomon
Original Assignee
Cancer Research Tech Ltd
Tusk Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd, Tusk Therapeutics Ltd filed Critical Cancer Research Tech Ltd
Priority claimed from PCT/EP2018/056312 external-priority patent/WO2018167104A1/en
Publication of MA49881A publication Critical patent/MA49881A/en
Publication of MA49881B1 publication Critical patent/MA49881B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'utilisation d'un anticorps anti-cd25, qui n'inhibe pas l'interaction il-2-cd25, avec une liaison améliorée pour activer des rs gamma fc qui conduisent à un épuisement efficace de cellules treg infiltrant les tumeurs et une meilleure maîtrise de tumeurs établies. Selon l'invention, la combinaison avec des anticorps anti-protéine-1 de mort cellulaire programmée améliore en outre le rejet tumoral.The present invention relates to the use of an anti-cd25 antibody, which does not inhibit il-2-cd25 interaction, with enhanced binding to activate rs gamma fc which leads to effective depletion of Treg cells infiltrating the tumors and better control of established tumors. According to the invention, the combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.

MA49881A 2017-03-17 2018-03-13 ANTI CD25 ANTICOPRS OPTIMIZED IN THEIR FC PART INVOLVING THE DEPLETION OF TUMOR-SPECIFIC CELLS MA49881B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17161717 2017-03-17
PCT/EP2018/056312 WO2018167104A1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion

Publications (2)

Publication Number Publication Date
MA49881A MA49881A (en) 2020-06-24
MA49881B1 true MA49881B1 (en) 2024-03-29

Family

ID=58387711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49881A MA49881B1 (en) 2017-03-17 2018-03-13 ANTI CD25 ANTICOPRS OPTIMIZED IN THEIR FC PART INVOLVING THE DEPLETION OF TUMOR-SPECIFIC CELLS

Country Status (2)

Country Link
MA (1) MA49881B1 (en)
PT (1) PT3596123T (en)

Also Published As

Publication number Publication date
MA49881A (en) 2020-06-24
PT3596123T (en) 2024-04-11

Similar Documents

Publication Publication Date Title
MA39313A1 (en) Anti-egfrviii antibodies and their uses in the treatment of various cancers
MA43466A1 (en) Treatments for uterine cancer
MX2019013033A (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof.
MA42073A1 (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
MA41879A1 (en) Novel peptides and peptide combination for use in immunotherapy against prostate cancer and other cancers
MX2020013169A (en) Camptothecin conjugates.
MA34546B1 (en) CD33 BINDING AGENTS
MA40801A1 (en) Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123
EA201991156A1 (en) ANTIBODIES TO Tim-3 FOR COMBINATION WITH ANTIBODIES TO PD-1
MA40497A (en) ANTIBODIES AND CHEMERICAL ANTIGENIC RECEPTORS SPECIFIC TO CD19
MA44101A (en) PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS
CR20190477A (en) Fc-optimized anti-cd25 for tumour specific cell depletion
MA43719B1 (en) PEPTIDE FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND SMALL CELL LUNG CANCER
MA38498B1 (en) Anti-lag-3 binding proteins
MA43460A1 (en) Novel peptides, peptide combinations and carriers for use in the immunotherapeutic treatment of various cancers
MA43435B1 (en) NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 25 - MRAX5-003)
MA42530B1 (en) Constructions of Bispecific Antibodies Binding to dll3 and cd3
MA43477A1 (en) Immunotherapy against melanoma and other cancers
MA50259A1 (en) Steroids and their antibody conjugates
MA43767B1 (en) Non-antagonistic antibodies directed against the alpha chain of the extracellular domain of the il-7 receptor and their use in the treatment of cancer
NO20071790L (en) Methods for using death receptor ligands and CD20 antibodies
EA200970607A1 (en) UNIVERSAL VACCINE FROM TUMOR CELLS FOR ANTI-CANCER THERAPY AND PREVENTION USE
MA43794B1 (en) Methods of predicting the utility of neoantigens for immunotherapy
FR3066240B1 (en) SUPPORT AND SUPPORT ASSEMBLY
MA49881B1 (en) ANTI CD25 ANTICOPRS OPTIMIZED IN THEIR FC PART INVOLVING THE DEPLETION OF TUMOR-SPECIFIC CELLS